AMH and neoplasm: The chemoprotective effects of AMH were first shown by Kano et al. (2017), who demonstrated that AMH administration (via AAV9 gene therapy or pump delivery of recombinant human AMH) could reversibly block primordial follicle activation in mice and reduce the effects of carboplatin, doxorubicin, or cyclophosphamide on follicle loss in a mouse tumour model.